Yeni tanı konulmuş glukoz metabolizma bozukluğu olan hastalarda serum visfatin konsatrasyonun değerlendirilmesi

Year 2019, , 401 - 406, 30.09.2019

Kamil Gönderen , İrem Bilgetekin Aysun Gönderen , Mehmet Yıldız

https://doi.org/10.31362/patd.540973

Abstract

Amaç: Visfatin, visseral adipoz doku tarafından
salgılanan, insülin-mimetik etkileri olan ve plazma glukoz seviyelerini düşüren
hücre içi bir enzimdir. Yeni tanı konulan glukoz metabolizma bozukluklarında
visfatinin rolü ile ilgili yapılan çalışmalar sınırlıdır. Bu çalışmanın amacı
bozulmuş açlık glukozu ve bozulmuş glukoz toleransı olan hastalarda visfatin
serum konsantrasyonunu değerlendirmektir.
Gereç ve yöntem: Anormal glukoz metabolizması tanısı alan 57 hasta, oral
glukoz tolerans testi (OGTT) sonuçlarına göre bozulmuş açlık glukozu (BAG) (n =
39) ve BAG+ bozulmuş glukoz toleransı (BGT) (n = 18) olarak alt gruplara
ayrıldı. Kontrol grubu, normal glukoz toleransı olan ve herhangi bir metabolik
bozukluğu olmayan 44 sağlıklı bireyden oluşuyordu. Tüm katılımcıların serum
lipidleri, yüksek duyarlı CRP, ürik asit, glikolize hemoglobin (HbA1c) ve serum
visfatin düzeyleri ölçüldü. Bulgular: BAG
grubunun visfatin düzeyi 93.92 ± 12.95, BAG + BGT grubunun 37.79 ± 29.36,
kontrol grubunun 43.96 ± 38.57 idi. Grupların serum visfatin düzeyleri arasında
istatistiksel olarak anlamlı fark vardı (p <0.001). BAG grubunun ortalama
visfatin düzeyi, BAG + BGT ve kontrol gruplarından istatistiksel olarak daha
yüksekti (sırasıyla p <0.001, p <0.001). BAG + BGT grubunun visfatin
düzeyi kontrol grubununkinden düşüktü, ancak aradaki fark istatistiksel olarak
anlamlı değildi (p = 0.785). Visfatin düzeyleri toplam kolesterol, HDL, LDL,
hsCRP, ferritin ve HbA1c düzeyleri ile negatif korelasyon gösterdi, TG, HOMA-ir
ve BMI değerleri ile pozitif korelasyon gösterdi, ancak bu iliĢkiler
istatistiksel olarak anlamlı değildi. Sonuç:
BAG olan hastaların visfatin düzeyleri sağlıklı kontrollerden daha
yüksekti, ancak visfatin seviyeleri HOMA-ir, BMI, TG, HDL, LDL, hsCRP,
ferritin, MPV, HbA1c ve kolesterol düzeyleri arasında anlamlı korelasyon
saptanmadı.

Keywords

Visfatin, Impaired Fasting Glucose

Visfatin concentration in patients with newly-diagnosed glucose metabolism disorders

Abstract

ABSTRACT

Purpose: Visfatin, protein secreted by visceral adipose tissue,
visfatin is an intracellular enzyme that has insulin-mimetic effects and lowers
plasma glucose levels. Data about the role of visfatin in newly diagnosed
glucose metabolism abnormalities are limited. The aim of the work was to assess
serum concentration of visfatin in impaired fasting glucose and impaired
glucose tolerance. Materials and
Methods: 57 patients with diagnosis of abnormal glucose metabolism were
divided into the subgroups according to the oral glucose tolerance test (OGTT)
results as impaired fasting glucose(IFG) (n=39) and IFG+ impaired glucose
tolerance (IGT) (n=18). The control group consisted of 44 healthy controls with
normal glucose tolerance and without any metabolic disorders. Serum lipids,
high sensitive CRP, uric acide, glycated haemoglobin (HbA1c) and serum visfatin
levels were measured in all participants.
Results: The mean visfatin level of IFG group was 93.92±12.95, IFG+IGT
group was 37.79±29.36 and control group was 43.96±38.57. There was
statistically significant difference between serum visfatin levels of the
groups (p<0.001). Mean visfatin level of IFG group was statistically higher
than IFG+IGT and control groups (respectively p<0.001, p<0.001). Mean
visfatin level of IFG+IGT group was lower than the control group however, the
difference was not statistically significant (p=0.785). Visfatin levels were
negatively correlated with total cholesterol, HDL, LDL, hsCRP, ferritin and
HbA1c levels, positively correlated with TG, HOMA-ir and BMI values, however
these relationships were not statistically significant. Conclusion: Visfatin levels of patients with IFG were higher than
healthy controls however, visfatin levels were not correlated with HOMA-ir,
BMI, TG, HDL, LDL, hsCRP, ferritin, MPV, HbA1c and cholesterol levels.

Keywords

Visfatin, Impaired Fasting Glucose

References

• Genuth S, Alberti KG, Bennett P et al. Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Follow-up report on the diagnosis of diabetes mellitus. Diabetes Care 2003; 26: 3160–3167. doi: 10.2337/diacare.26.11.3160.
• Temd diabetes mellitus ve komplikasyonlarının tanı, tedavi ve izlem kılavuzu-2018
• S Ognjanovic, S Bao, S Y Yamamoto, J Garibay-Tupas, B Samal and G D Bryant-Greenwood. Genomic organization of the gene coding for human pre-B-cell colony enhancing factor and expression in human fetal membranes. J. Mol. Endocrinol. 2001; 26:107–117.
• Matthews DR, Hasker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in men. Diabetologia 1985, 28: 412-9.
• Lopez-Bermejo A, Chico-Julia B, Fernandez-Balsells M, et al. Serum visfatin increases with progressive beta-cell deterioration. Diabetes 2006; 55(10): 2871–2875.
• Brown JE, Onyango DJ, Ramanjaneya M, et al. Visfatin regulates insulin secretion, insulin receptor signalling and mRNA expression of diabetes-related genes in Mouse pancreatic beta-cells. J Mol Endocrinol 2010; 44: 171–178.
• Chen MP, Chung FM, Chang DM, et al. Elevated plasma level of visfatin/pre-B cell colony-enhancing factor in patients with type 2 diabetes mellitus. J Clin Endocrinol Metab 2006, 91: 295-9.
• Krzyzanowska K, Krugluger W, Mittermayer F, et al. Increased Visfatin visfatin concentrations in women with gestational diabetes mellitus. Clin Sci (Lond) 2006, 110: 605-9.
• Stephens JM, Vidal-Puig AJ. An update on visfatin/pre-B cell colonyenhancing factor, a ubiquitously expressed, illusive cytokine that is regulated in obesity. Curr Opin Lipidol 2006; 17: 128–131. doi: 10.1097/01. mol.0000217893.77746.4b.
• Chang YH, Chang DM, Lin KC et al. Visfatin in overweight/obesity, type 2 diabetes mellitus, insulin resistance, metabolic syndrome and cardiovascular diseases: a meta-analysis and systemic review. Diabetes Metab Res Rev 2011; 27: 515–527. doi: 10.1002/dmrr.1201.
• Visfatin in overweight/obesity, type 2 diabetes mellitus, insulin resistance, metabolic syndrome and cardiovascular diseases: a meta-analysis and systemic review. Diabetes Metab Res Rev 2011; 27: 515–527.
• Toruner F, Altinova AE, Bukan N. et al. Plasma visfatin concentrations in subjects with type 1 diabetes mellitus. Horm Res 2009;72:33-37.
• Nüsken KD, Nüsken E, Petrasch M et al. Preanalytical influences on the measurement of visfatin by enzyme immuno assay. Clin Chim Acta 2007;382: 154–156. doi: 10.1016/j.cca.2007.04.004.
• Körner A, Garten A, Blüher M et al. Molecular characteristics of serum visfatin and differential detection by immunoassays. J Clin Endocrinol Metab 2007; 92: 4783–4791. doi: http: //dx.doi.org/10.1210/jc.2007-1304.
• Zahorska-Markiewicz B, Olszanecka-Glinianowicz M,Janowska J, et al. Serum concentration of visfatin in obese women. Metabolism 2007;56:1131-1134.
• Kamińska A, Kopczyńska E, Bronisz A, et al. An evaluation of visfatin levels in obese subjects. Endokrynol Pol 2010;61:169-173.
• Davutoglu M, Ozkaya M, Guler E, et al. Plasma visfatin concentrations in childhood obesity: relationships to insulin resistance and anthropometric indices. Swiss Med Wkly 2009;139:22-27.
• Berndt J, Klöting N, Kralisch S, et al. Plasma visfatin concentrations and fat-specific mRNA expression in humans. Diabetes 2005;54:2911-2916.
• Pagano C, Pilon C, Olivieri M, et al. Reduced plasma visfatin/pre B-cell colony enhancing factor in obesity is not related to insulin resistance in humans. J Clin Endocrinol Metab 2006;91:3165-3170.